HLA-A*02-B*46 haplotype: an adverse prognostic factor in Han patients with nasopharyngeal carcinoma.
- Author:
Ruo-Zheng WANG
1
;
Dian-Gang ZHANG
1
;
Ran WU
1
;
Yun-Hui HU
1
;
Yan-Chun PENG
2
;
Cheng CHANG
1
;
Tao DONG
3
;
Xi-Yan WANG
1
Author Information
1. Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, 830011, China.
2. MRC Human Immunology Unit, Radcliffe Department of Medicine, Oxford University, Oxford, OX3 9DS, UK.
3. Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, 830011, China. tao.dong@imm.ox.ac.uk.
- Publication Type:Journal Article
- Keywords:
human leukocyte antigens;
metastasis;
nasopharyngeal carcinoma;
phenotype;
prognosis
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Biomarkers, Tumor;
genetics;
Carcinoma;
Child;
Disease-Free Survival;
Female;
HLA-A Antigens;
genetics;
HLA-B Antigens;
genetics;
Haplotypes;
Humans;
Male;
Middle Aged;
Nasopharyngeal Neoplasms;
genetics;
pathology;
Neoplasm Metastasis;
Neoplasm Staging;
Prognosis;
Retrospective Studies
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(5):700-704
- CountryChina
- Language:English
-
Abstract:
Epidemiological studies have shown that human leukocyte antigen (HLA) allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma (NPC), and in a previous study, we showed that HLA-B*46 and HLA-A*02-B*46 haplotypes were strongly associated with NPC susceptibility. In this retrospective study, we investigated the phenotype of the HLA-A and HLA-B alleles and haplotypes and correlated these data to the clinical and pathological parameters of NPC to understand the role of HLA alleles and haplotypes in NPC prognosis. The cohort comprised 117 NPC patients from a Han population in Xinjiang. The local recurrence-free survival (LRFS), distant metastasis- free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were analyzed. The 5-year DMFS of the HLA-A*02-B*46 haplotype carriers and non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be a prognostic factor for LRFS, DFS, and OS (P=0.032, 0.040, and 0.013, respectively). We found that the HLA-A*02-B*46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC.
